GlobalData on MSN15h
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nodBefore the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
MedPage Today on MSN1d
FDA OKs New Option for Rare Immune-Mediated VasculitisEGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
The randomized, double-blind, placebo-controlled phase 3 MATINEE study evaluated the safety and efficacy of mepolizumab in patients with COPD and type 2 inflammation.
Adding GSK’s mepolizumab to standard inhaled treatment for COPD reduces the frequency of exacerbations in patients with type ...
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback